Summer Sale
50% off Premium Yearly
NASDAQ:AMGN
Amgen Inc. (AMGN)
Financials 
Technical Analysis 
Jun 15, 2026, 12:00 amThis summary was created by AI, based on 20 opinions in the last 12 months.
Amgen Inc. is generally perceived as a well-managed and innovative biotech company, characterized by a strong portfolio with 15 products witnessing double-digit revenue growth. Analysts note the company's potential due to its attractive valuation, with a forward P/E ratio under 20x and a solid dividend yield around 3.23% to 3.46%. Investors are optimistic about Amgen's development of its GLP-1 drug, which is currently in phase 3 testing and has the potential to be a game-changer in the weight-loss market. Despite facing some challenges, including trial misses and growing competition, many experts recommend holding or buying shares, highlighting its safety as a large-cap biotech investment. Overall, Amgen is seen as a stable choice for investors looking for exposure to the biotech sector amidst a fluctuating healthcare market.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium content
He's surprised with how strongly shares are soaring on phase 3 trial results of their obesity drug. They're a little late to the party in these drugs, but theirs you would take less often their than peers'. Also, a recent acquisition makes them double-digit revenue growers and is accretive. Loves the dividend growth too.
Kevin SimpsonLegacy products that continue to do well. But new products are contributing well, too. Latest acquisition adding significantly to growth profile. Reasonable multiple of 12-13x, good prospects for growth. Out of favour, along with many healthcare stocks. Good, long-term hold.
Premium contentAs AI begins to play a larger role in medical intervention, AMGN is well positioned to benefit. It has increased its dividend for 11 consecutive years. It trades at 21x earnings and supports a robust 135% ROE. We recommend setting a stop-loss at $210, looking to achieve $319 -- upside potential of 18%. Yield 3.2%
(Analysts’ price target is $308.33)His impression was that the Phase 1 trial did go well. Management emphasized long way to go before it would have a monetary impact. Stock did sell off when earnings released. Still likes it. Recent acquisition will be positive for future earnings and revenue growth. Not expensive. Lots in pipeline.
Gordon ReidDrop mainly due to NVO and LLY leading the pack on weight-loss drugs. Still, AMGN has a great lineup of drugs, revenues should grow over time. Ranks well for him. More beta than a normal healthcare stock. Now at 100-day MA, almost oversold. Makes sense from an earnings growth perspective, high single digits. Fine name, he just prefers others.
Down a bit on earnings report this morning, but overlook that, short-term reaction. Phase 1 weight-loss drug primed to compete with LLY's, though not yet being promoted as its next blockbuster. Much more modest multiple than LLY.
Gordon ReidReasonable multiple, mid-high teens. Good growth rate, highly predictable. Has a GLP-1 candidate, good results in Phase 1 testing. 17% of revenue goes back into R&D.
Gordon Reid
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20scale(-1,%201)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
'%20fill='%23ffffff'%3e%3cg%20id='Pager'%20transform='translate(423.000000,%201755.000000)'%3e%3cpath%20d='M243.295367,17.286474%20C243.68919,16.9045087%20244.327703,16.9045087%20244.721525,17.286474%20L249,21.4361302%20L253.278475,17.286474%20C253.672297,16.9045087%20254.31081,16.9045087%20254.704633,17.286474%20C255.098456,17.6684393%20255.098456,18.2877274%20254.704633,18.6696927%20L249.35654,23.856763%20C249.159628,24.0477457%20248.840372,24.0477457%20248.64346,23.856763%20L243.295367,18.6696927%20C242.901544,18.2877274%20242.901544,17.6684393%20243.295367,17.286474%20Z'%20id='Path'%20transform='translate(249.000000,%2020.500000)%20rotate(-90.000000)%20translate(-249.000000,%20-20.500000)%20'%3e%3c/path%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
Owns this instead of NVO. A much less troublesome valuation. Also has a weight-loss drug in trial. You want to be in before the good news, not after.